CVC Capital Partners ("CVC") today announced that funds advised by CVC have finalised the sale of part of their stake in Jintian Pharmaceutical Group Ltd ("Jintian"), a leading pharmaceutical retailer and distributor in Northeast China, which is listed on the Hong Kong Stock Exchange.
Funds advised by CVC have sold 185,500,000 shares at the price of HK$3.29 per share, and retain a stake of 6.9% in the business.
CVC funds made an initial investment in Jintian in October 2011, acquiring a 24.2% stake. The company successfully completed its listing on the Hong Kong Stock Exchange in December 2013.
Francis Leung, Managing Partner and Chairman of Greater China for CVC, commented: "We are pleased that CVC funds invested and remain invested in Jintian. The recent sale of part of the CVC funds' investment in the business is in line with our usual process of managing CVC fund investments and has realised a solid return for our investors. CVC will continue to support the management of Jintian in executing its strategic objectives."
CVC Credit provides debt facilities to American Heart of Poland through its Capital Solutions strategy
Grupo GSH’S next stage of growth backed by leading global investor CVC
CVC DIF and VNG AG strengthen the future of BALANCE through a growth partnership
Mehiläinen agrees the acquisitions of Regina Maria and MediGroup and welcomes Hellman & Friedman as a new shareholder alongside CVC
CVC, Nordic Capital and ADIA complete acquisition of Hargreaves Lansdown to accelerate and enhance its transformation plan and deliver on its growth potential
CVC closes third generation Strategic Opportunities fund at €4.61 billion